XSTO
IDLDX
Market cap7mUSD
Oct 30, Last price
0.31SEK
1D
-5.71%
1Q
-26.98%
Jan 2017
-95.51%
IPO
-91.64%
Name
AroCell AB (publ)
Chart & performance
P/E
—
P/S
1.26
EPS
—
Vol. 1Y
77.69%
Shs. 5Y
41.80%
Rev. 5Y
164.62%
Div Yld LY
—
Div Yld TTM
—
Revenues
57m
+33.45%
Net income
-42m
L-28.41%
CFO
-2m
L-82.45%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Key people
Claes Post
Chairman of the Board · since 2017
Chief Executive Officer · since 2021
Ellen Dittberner
Chief Financial Officer · since 2025
Gustav Stone
Chief Operating Officer
Anne-christine Nilsson
Chief Scientific Officer
Sofia Forsberg
Chief Quality Officer
Senior Director Regulatory Affairs · since 2019
Gunnar Steineck
Chief Medical Officer · since 2021
Marie Torstensson
Chief Sales Officer, Laboratory
Gunnar Wahlberg
Chief Sales Officer, Rapid
Per-anders Abrahamsson
Director · since 2022
Karin Eriksson-Vidblom
Director · since 2019
Agneta Franksson
Director · since 2017
Charlotta Ljungqvist
Director · since 2021
Eva Nordstrom
Director · since 2020
Max Pihlqvist
Director · since 2022
Headquarters & legal address
Karlsbodavägen 39
Bromma, AB 168 67
SE
Bromma, AB 168 67
SE
Address
Karlsbodavagen 39
Bromma, AB 168 67
SE
Bromma, AB 168 67
SE
Previous name
AroCell AB (publ)
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||